Tag Archives: VRUS

What the fuss Affymax, Idenix Pharmaceuticals and Cameron International?

Posted on December 16, 2011 by Josie Middleton

In this report: Affymax (NASDAQ:AFFY), Idenix Pharmaceuticals (NASDAQ:IDIX) and Cameron International Corp. (NYSE:CAM).

Affymax (NASDAQ:AFFY) has dropped by more than 10 percent today after the company announced yesterday after the markets closed that it has decided not to commercialize peginesatide …

Posted in Latest Headlines, Reports | Tagged AFFY, Affymax, BP, CAM, Cameron International Corp., commercialization, company, deepwater horizon, developing, hepatitis C, Idenix Pharmaceuticals, IDIX, investors, killed, macondo, markets, NASDAQ, NASDAQ:AFFY, NASDAQ:IDIX, NASDAQ:VRUS, NYSE, NYSE:CAM, Peginesatide, Pharmasset, report, rights, spill, Takeda, treatments, VRUS, well | Comments Off

Big time losers and the reasons why (INHX, QTWW, STEM)

Posted on December 16, 2011 by Cameron White

In this report: Inhibitex (NASDAQ:INHX), Quantum Fuel Systems Technologies (NASDAQ:QTWW) and StemCells (NASDAQ:STEM).

Inhibitex (NASDAQ:INHX) as well as other companies developing hepatitis C virus treatments dropped lower on Friday after Pharmasset (NASDAQ:VRUS) stated that it will amend the design of …

Posted in Latest Headlines, Reports | Tagged common stock, company, corporate, gross proceeds, hepatitis C, Inhibitex, INHX, investors, NASDAQ:INHX, NASDAQ:QTWW, NASDAQ:STEM, NASDAQ:VRUS, offering, Pharmasset, Phase 2b, public offering, QTWW, Quantum, Quantum Fuel Systems Technologies, STEM, StemCells, trading, treatments, trial, unit, VRUS, warrant | Comments Off

What’s up Inhibitex, Pharmasset and Global Education & Technology?

Posted on November 21, 2011 by Martin Timble

In this report: Global Education & Technology (NASDAQ:GEDU), Pharmasset (NASDAQ:VRUS) and Inhibitex (NASDAQ:INHX).

Global Education & Technology (NASDAQ:GEDU) rallied by more than 97 percent on during early trading on Monday after it was reported that British publishing group Pearson Plc. would …

Posted in Latest Headlines, Reports | Tagged acquire, agreed, biopharmaceutical, cash, CEO, China, deal, drugs, GEDU, Gilead Sciences, Global Education & Technology, growth, healthcare, hepatitis C, Inhibitex, INHX, investors, NASDAQ, NASDAQ:GEDU, NASDAQ:INHX, NASDAQ:VRUS, Pearson, Pharmasset, premium, publishing group, report, sector, shares, takeover, trading, VRUS | Comments Off

What’s up Akorn, Pharmasset and Corinthian Colleges?

Posted on November 1, 2011 by Cameron White

In this report: Akorn Inc. (NASDAQ:AKRX), Pharmasset Inc. (NASDAQ:VRUS) and Corinthian Colleges (NASDAQ:COCO).

Akorn Inc. (NASDAQ:AKRX) has gained more than 11 percent today after the company reported a record third quarter. The company reported revenue of $36.7 million, up 69 …

Posted in Latest Headlines, Reports | Tagged 2012, adjusted, Akorn Inc., AKRX, Analysts, clinical trials, COCO, company, Corinthian Colleges, drug, earnings, EBITDA, experimental, fiscal, full-year, hepatitis C, late stage, marketing approval, NASDAQ:AKRX, NASDAQ:COCO, NASDAQ:VRUS, net income, outlook, Pharmasset Inc., predicted, profits, quarter, reported, results, revenue, ribavirin, trades, VRUS, Wall Street | Comments Off

Big time losers and the reasons why (CALX, VRUS, BAS, TZOO)

Posted on October 21, 2011 by Martin Timble

In this report: Calix Inc. (NYSE:CALX), Pharmasset Inc. (NASDAQ:VRUS), Basic Energy Services (NYSE:BAS) and Travelzoo Inc. (NASDAQ:TZOO).

Calix Inc. (NYSE:CALX) has dropped more than 21 percent today after the company’s latest quarterly results. The company reported a third quarter profit …

Posted in Latest Headlines, Reports | Tagged Abbott Laboratories, ABT, BAS, Basic Energy Services, CALX, communications software, company, earnings, expectations, hepatitis C, interferon, investors, NASDAQ, NASDAQ:TZOO, NASDAQ:VRUS, net income, net loss, NYSE, NYSE:ABT, NYSE:BAS, NYSE:CALX, patients, Pharmasset Inc., profitCalix Inc., quarterly, results, revenue, spike, study, therapy, trades, Travelzoo Inc., TZOO, VRUS | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.